ALS
Sensorion SA
Stock
Stock
ISIN: FR001401A9Z0
Ticker: ALSEN
FR001401A9Z0
ALSEN
Price
Price
CHART BY
Frequently asked questions
What is Sensorion SA's market capitalization?
The market capitalization of Sensorion SA is 87.72M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Sensorion SA?
Sensorion SA's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$4.382. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Sensorion SA's stock?
Currently, 6 analysts cover Sensorion SA's stock, with a consensus target price of 40.20. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Sensorion SA?
Sensorion SA's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -39.94M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Sensorion SA?
Sensorion SA has a free cash flow of -26.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Sensorion SA have, and what sector and industry does it belong to?
Sensorion SA employs approximately 63 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Sensorion SA's shares?
The free float of Sensorion SA is 5.21M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- 87.72M
- EPS (TTM)
- -$4.382
- Free Float
- 5.21M
- EBITDA (TTM)
- -39.94M
- Free Cashflow (TTM)
- -26.54M
Pricing
- 1D span
- $9.317$10.40
- 52W span
- $5.886$46.33
Analyst Ratings
The price target is 40.20 and the stock is covered by 6 analysts.
Buy
5
Hold
1
Sell
0
Information
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company was founded by Christian Chabbert, Gilles Desmadryl, Sylvain Bartolami and Sophie Gaboyard in 2009 and is headquartered in Montpellier, France.
- Employees
- 63
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- FR001401A9Z0
- Primary Ticker
- ALSEN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet